These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24083757)

  • 21. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
    Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy response in head and neck cancer - evaluation of the primary tumour site.
    Sjövall J; Brun E; Almquist H; Kjellén E; Wahlberg P
    Acta Otolaryngol; 2014 Jun; 134(6):646-51. PubMed ID: 24707930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT.
    Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
    J Radiat Res; 2015 May; 56(3):553-60. PubMed ID: 25829531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.
    Yao M; Smith RB; Hoffman HT; Funk GF; Lu M; Menda Y; Graham MM; Buatti JM
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):9-14. PubMed ID: 18930358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment.
    Yao M; Luo P; Hoffman HT; Chang K; Graham MM; Menda Y; Tan H; Buatti JM
    Am J Clin Oncol; 2007 Jun; 30(3):264-70. PubMed ID: 17551303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
    Zundel MT; Michel MA; Schultz CJ; Maheshwari M; Wong SJ; Campbell BH; Massey BL; Blumin J; Wilson JF; Wang D
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e825-32. PubMed ID: 21300450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Pretreatment and 3-Month
    Mayo Z; Seyedin SN; Mallak N; Mott SL; Menda Y; Graham M; Anderson C
    Ann Otol Rhinol Laryngol; 2019 Jul; 128(7):595-600. PubMed ID: 30808209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound.
    Fakhry N; Michel J; Colavolpe C; Varoquaux A; Dessi P; Giovanni A
    Clin Otolaryngol; 2012 Jun; 37(3):197-206. PubMed ID: 22520870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma.
    Vernon MR; Maheshwari M; Schultz CJ; Michel MA; Wong SJ; Campbell BH; Massey BL; Wilson JF; Wang D
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):678-84. PubMed ID: 18262086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
    Sagardoy T; Fernandez P; Ghafouri A; Digue L; Haaser T; de Clermont-Galleran H; Castetbon V; de Monès E
    Head Neck; 2016 Apr; 38 Suppl 1():E1271-6. PubMed ID: 26315809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer.
    Demirci U; Coskun U; Akdemir UO; Benekli M; Kapucu O; Ozkan S; Cakir T; Baykara M; Buyukberber S
    Asian Pac J Cancer Prev; 2011; 12(7):1817-20. PubMed ID: 22126572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance and predictive performance of volume-based parameters of F-18 FDG PET/CT in squamous cell head and neck cancers.
    Sager S; Asa S; Yilmaz M; Uslu L; Vatankulu B; Halaç M; Sönmezoglu K; Kanmaz B
    J Cancer Res Ther; 2014; 10(4):922-6. PubMed ID: 25579529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy.
    Taghipour M; Sheikhbahaei S; Wray R; Agrawal N; Richmon J; Kang H; Subramaniam RM
    AJR Am J Roentgenol; 2016 May; 206(5):1093-100. PubMed ID: 26999264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.